First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
Takeda’s manufacturing site at Lessines, Belgium, is contributing to the production of the clinical material for the NIH Phase 3 trial, emphasizing the importance of Belgium as a pharmaceutical hub.
The General Data Protection Regulation (GDPR) acknowledges the free movement of personal data within the European Union (EU), while it restricts transfers of personal data to countries outside the EU.